References
- Lonial S, Weis BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387:1551–1560.
- Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319–1331.
- Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754–766.
- Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017;130:974–981.
- Darzalex (daratumumab) [prescribing information]. Horsham (PA): Janssen Biotech, Inc; 2017.
- Chari A, Mark TM, Krishnan A, et al. Use of montelukast to reduce infusion reactions in an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Blood. 2019;128:2142.
- Usmani SZ, Jakubowiak A, Chari A, et al. Split dosing of daratumumab (D) in a phase 1b study of D plus carfilzomib (K)-based regimens in patients (pts) with multiple myeloma (MM). Ann Oncol. 2017;28:v355–v371.
- Xu S, Moreau P, Usmani SZ, et al. Split first dose administration of daratumumab for the treatment of patients with multiple myeloma (MM): clinical pharmacology and population pharmacokinetic analyses (PK). Blood. 2018;653:1970.
- Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378:518–528.
- Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373:1207–1219.
- Cejalvo MJ, Legarda M, Abella E, et al. Activity and safety of daratumumab monotherapy in patients in relapsed and refractory multiple myeloma requiring dialysis: preliminary results of Spanish, retrospective, multicenter trial. Blood. 2017;130:1866.
- Rocchi S, Tacchetti P, Pantani L, et al. Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma. Haematologica. 2018;103:e277–e278.